Table 1.
Baseline characteristics of subjects randomized to the treatment period (Safety analysis set, N = 23).
| Baseline Characteristics | Arm 1 N = 11 |
Arm 2 N = 12 |
|---|---|---|
| Sex | ||
| Male: n (%) | 4 (36.4) | 5 (41.7) |
| Female: n (%) | 7 (63.6) | 7 (58.3) |
| Race | ||
| Caucasian: n (%) | 11 (100) | 12 (100) |
| Median age: years (range) | 64 (43–74) | 71 (44–80) |
| BMI: kg/m2 (standard deviation) | 24.4 (3.9) | 23.3 (2.5) |
| ECOG: n (%) | ||
| 0 | 4 (36.4) | 3 (25.0) |
| 1 | 7 (63.6) | 9 (75.0) |
| Pancreatic adenocarcinoma | ||
| Type | ||
| Locally advanced: n (%) | 2 (18.2) | 2 (16.7) |
| Metastatic: n (%) | 9 (81.8) | 10 (83.3) |
BMI = body mass index, ECOG = Eastern Cooperative Oncology Group.